ISSN: 2167-0501
+44-77-2385-9429
Laurence Dubrez
Smac mimetics are a very promising new class of anticancer agents demonstrating an acceptable safety profile and efficacy in some preclinical models of cancers when used as a single agent or in combination with conventional or nonconventional therapies. Future preclinical and clinical trials could enlarge their spectral of action in inflammatory, fibrotic and infectious diseases.